Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.

Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord.

HIV Med. 2013 Nov;14(10):614-23. doi: 10.1111/hiv.12068. Epub 2013 Jul 19.

2.

Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.

Berenguer J, Zamora FX, Carrero A, Von Wichmann MA, Crespo M, López-Aldeguer J, Aldámiz-Echevarría T, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Esteban H, Bellón JM, González-García J; GESIDA HIVHCV Cohort Study Group.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):280-7. doi: 10.1097/QAI.0000000000000156.

PMID:
25157646
3.

Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.

Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group.

HIV Med. 2013 Aug;14(7):430-6. doi: 10.1111/hiv.12023. Epub 2013 Mar 5.

4.

Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.

Fernández-Montero JV, Barreiro P, Vispo E, Labarga P, Sánchez-Parra C, de Mendoza C, Treviño A, Soriano V.

Antivir Ther. 2014;19(3):287-92. doi: 10.3851/IMP2703. Epub 2013 Nov 5.

PMID:
24192598
5.

A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.

Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, Aichelburg MC, Schmied B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab and Vienna HIV & Liver Study Group.

Antivir Ther. 2012;17(7):1327-34. doi: 10.3851/IMP2349. Epub 2012 Sep 5.

PMID:
22948263
6.

Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.

Barcaui HS, Tavares GC, May SB, Brandão-Mello CE, Amendola Pires MM, Barroso PF.

PLoS One. 2013 Jul 9;8(7):e67734. doi: 10.1371/journal.pone.0067734. Print 2013.

7.

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group.

Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020.

PMID:
19575364
8.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.

Gut. 2000 Nov;47(5):694-7.

9.

Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.

Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, Ojanguren I, Barluenga E, Videla S, Planas R, Clotet B, Tural C.

HIV Med. 2014 Apr;15(4):203-12. doi: 10.1111/hiv.12105. Epub 2013 Nov 19.

10.

Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.

Ingiliz P, Valantin MA, Preziosi P, Finzi L, Pais R, Fedchuk L, Dominguez S, Katlama C, Poynard T, Benhamou Y.

J Hepatol. 2012 Jan;56(1):49-54. doi: 10.1016/j.jhep.2011.05.028. Epub 2011 Jul 23.

PMID:
21781946
11.

Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.

Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V.

J Viral Hepat. 2014 Jul;21(7):475-9. doi: 10.1111/jvh.12180. Epub 2013 Oct 6.

PMID:
24750394
12.

Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.

Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, Christensen S, Köppe S, Kundi M, Rieger A, Peck-Radosavljevic M.

Antivir Ther. 2011;16(6):815-24. doi: 10.3851/IMP1831.

PMID:
21900713
13.

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord.

J Hepatol. 2013 Aug;59(2):213-20. doi: 10.1016/j.jhep.2013.04.005. Epub 2013 Apr 11.

PMID:
23583272
14.

Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.

Casado JL, Quereda C, Moreno A, Pérez-Elías MJ, Martí-Belda P, Moreno S.

J Viral Hepat. 2013 Dec;20(12):829-37. doi: 10.1111/jvh.12108. Epub 2013 Apr 25.

PMID:
24304452
15.

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.

Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.

Antivir Ther. 2004 Aug;9(4):505-9.

PMID:
15456081
16.

Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.

Barreiro P, Martín-Carbonero L, Núñez M, Rivas P, Morente A, Simarro N, Labarga P, González-Lahoz J, Soriano V.

Clin Infect Dis. 2006 Apr 1;42(7):1032-9. Epub 2006 Feb 21.

PMID:
16511772
17.

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.

Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, Moore RD, Thomas DL, Sulkowski MS.

JAMA. 2012 Jul 25;308(4):370-8. doi: 10.1001/jama.2012.7844.

18.

Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.

Labarga P, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano V.

Antivir Ther. 2015;20(3):329-34. doi: 10.3851/IMP2909. Epub 2014 Nov 5.

PMID:
25372299
19.

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T; MultivirC Group.

Hepatology. 2001 Aug;34(2):283-7.

PMID:
11481613
20.

Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.

Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Cooper C; CANOC Collaboration.

AIDS. 2014 Jan 2;28(1):121-7. doi: 10.1097/QAD.0000000000000020.

PMID:
24413263

Supplemental Content

Support Center